BridgeBio Oncology Therapeutics Ord Shs

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, BridgeBio Oncology Therapeutics Ord Shs had 52.66M in cash and cash equivalents.

BridgeBio Oncology Therapeutics Ord Shs reported 37.28M in total liabilities as of the latest reported quarter, including 35.04M in current liabilities and 2.24M in non-current liabilities.

As of the latest reported quarter, BridgeBio Oncology Therapeutics Ord Shs's total assets were 448.38M, consisting of 432.40M in current assets and 15.98M in non-current assets.

BridgeBio Oncology Therapeutics Ord Shs reported 411.10M in total shareholders' equity as of the latest reported quarter.